BTEE:LSE:LSE-iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (USD)

ETF | Others |

Last Closing

USD 6.05

Change

+0.13 (+2.23)%

Market Cap

USD 0.49B

Volume

0.02M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-23 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R15:LSE SoftBank Group Corp.

N/A

USD 9,217.80B
0R1E:LSE Nintendo Co. Ltd.

N/A

USD 7,596.04B
0R1O:LSE Amazon.com Inc.

+4.00 (+2.20%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

+26.15 (+3.08%)

USD 618.20B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

+0.21 (+1.19%)

USD 617.54B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.09 (+0.61%)

USD 617.54B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
XDJP:LSE Xtrackers Nikkei 225 UCITS ETF..

+20.00 (+0.98%)

USD 348.03B
0QZK:LSE Coca-Cola Co.

-1.05 (-1.69%)

USD 266.08B
0QZO:LSE 0QZO

+1.70 (+1.53%)

USD 258.54B

ETFs Containing BTEE:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.22% 13% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.22% 13% F 26% F
Trailing 12 Months  
Capital Gain -1.55% 21% F 38% F
Dividend Return 0.23% 40% F 69% C-
Total Return -1.31% 20% F 38% F
Trailing 5 Years  
Capital Gain 25.38% 50% F 61% D-
Dividend Return 0.66% 25% F 16% F
Total Return 26.04% 47% F 58% F
Average Annual (5 Year Horizon)  
Capital Gain 6.69% 61% D- 65% D
Dividend Return 6.80% 60% D- 65% D
Total Return N/A 50% F 98% N/A
Risk Return Profile  
Volatility (Standard Deviation) 19.78% 36% F 50% F
Risk Adjusted Return 34.39% 56% F 68% D+
Market Capitalization 0.49B 70% C- 60% D-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.